Breakthrough Study Highlights Promising New Treatment for Anxiety in Adolescents

During Stress Awareness month, new research from physician and leading post-traumatic stress injury expert Dr. Eugene Lipov is shedding light on a promising, non-pharmaceutical treatment for anxiety in adolescents—offering hope amid rising rates of youth mental health challenges.

Presented at the Anxiety and Depression Association of America Conference 2026, the study examines the use of cervical sympathetic block (CSB) (widely known as stellate ganglion block) a procedure targeting the body’s sympathetic nervous system, in pediatric patients with anxiety disorders.

The research represents the largest cohort to date evaluating CSB in an adolescent population and demonstrates significant reductions in anxiety symptoms. Notably, participants experienced a decrease in GAD-7 scores nearly twice the minimal clinically important difference, indicating meaningful and measurable improvement.

Anxiety disorders are among the most common mental health conditions affecting children and adolescents, with recent data estimating that nearly 30% of U.S. students experience anxiety or depression-related concerns. While traditional treatments such as SSRIs can be effective, they are often associated with side effects that lead to discontinuation, underscoring the need for alternative approaches.

Dr. Lipov’s research targets a key underlying driver of anxiety: overactivity of the sympathetic nervous system. By administering a local anesthetic to the cervical sympathetic ganglia, CSB works to regulate this response—potentially addressing the root cause of symptoms rather than solely managing them.

“Given the prevalence of anxiety disorders in adolescents and the limitations of existing treatments, exploring innovative approaches like stellate ganglion block is essential,” said Dr. Lipov. “Our findings suggest this could be a viable option for improving outcomes in younger populations.”

Previous studies have demonstrated the effectiveness of this approach in adults with PTSD and anxiety, but its application in pediatric populations has remained largely unexplored—until now.

These findings mark an important step forward in expanding treatment options for young people and highlight the need for continued research into therapies that address the biological mechanisms underlying anxiety.

For more information, please visit www.dreugenelipov.com